Type 2 Diabetes Treatment Synjardy Now Available in Pharmacies

Synjardy, a type 2 diabetes treatment, is now available by prescription in US pharmacies.

Boehringer Ingelheim’s and Eli Lilly and Company’s empagliflozin/metformin hydrochloride tablets were originally approved in August 2015 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who are not adequately controlled on a regimen containing empagliflozin or metformin alone.

It was also indicated for patients already being treated with empagliflozin and metformin.

"Boehringer Ingelheim and Lilly are committed to helping improve care for adults with type 2 diabetes," said Thomas Seck, vice president of Clinical Development and Medical Affairs for Metabolism at Boehringer Ingelheim, in a press release. "As part of that effort, we are proud to make Synjardy, the third product from our diabetes alliance containing Jardiance, available to patients soon after its FDA approval."

Adverse effects associated with Synjardy include dehydration, low blood sugar, headache, and drowsiness. Patients may also experience kidney problems and vaginal yeast infections.

The diabetes drug carries a boxed warning for risk of lactic acidosis due to metformin accumulation, as well.

Synjardy is not indicated for type 1 diabetes or diabetic ketoacidosis.